AIMZ Investment Advisors LLC Lowers Holdings in Medtronic PLC $MDT

AIMZ Investment Advisors LLC trimmed its stake in Medtronic PLC (NYSE:MDT) by 1.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 17,747 shares of the medical technology company’s stock after selling 195 shares during the quarter. AIMZ Investment Advisors LLC’s holdings in Medtronic were worth $1,595,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Boston Partners boosted its stake in Medtronic by 122.8% in the 1st quarter. Boston Partners now owns 6,912,055 shares of the medical technology company’s stock worth $619,460,000 after purchasing an additional 3,809,450 shares in the last quarter. Ameriprise Financial Inc. increased its stake in Medtronic by 28.8% during the 1st quarter. Ameriprise Financial Inc. now owns 15,481,028 shares of the medical technology company’s stock valued at $1,391,141,000 after purchasing an additional 3,461,221 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Medtronic by 42.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,059,135 shares of the medical technology company’s stock worth $903,915,000 after buying an additional 3,017,849 shares during the last quarter. Nuveen LLC purchased a new position in Medtronic in the first quarter worth about $260,649,000. Finally, Burgundy Asset Management Ltd. bought a new position in shares of Medtronic in the fourth quarter worth approximately $174,329,000. 82.06% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

MDT has been the subject of several analyst reports. BTIG Research reissued a “neutral” rating on shares of Medtronic in a research report on Friday, July 11th. Needham & Company LLC reiterated a “hold” rating on shares of Medtronic in a research note on Thursday, August 14th. Royal Bank Of Canada decreased their price target on Medtronic from $105.00 to $101.00 and set an “outperform” rating for the company in a research note on Thursday, May 22nd. Sanford C. Bernstein upped their price target on Medtronic from $97.00 to $98.00 and gave the company an “outperform” rating in a report on Wednesday. Finally, Wells Fargo & Company lifted their price objective on Medtronic from $98.00 to $100.00 and gave the stock an “overweight” rating in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $101.15.

Medtronic Price Performance

NYSE MDT opened at $92.6210 on Friday. The stock has a market capitalization of $118.72 billion, a price-to-earnings ratio of 25.52, a PEG ratio of 2.36 and a beta of 0.80. Medtronic PLC has a 1-year low of $79.29 and a 1-year high of $96.25. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.85 and a quick ratio of 1.42. The business’s fifty day moving average price is $89.73 and its 200-day moving average price is $88.01.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, August 19th. The medical technology company reported $1.26 EPS for the quarter, topping the consensus estimate of $1.23 by $0.03. Medtronic had a return on equity of 14.56% and a net margin of 13.63%.The company had revenue of $8.58 billion during the quarter, compared to analyst estimates of $8.37 billion. During the same quarter in the previous year, the company posted $1.23 earnings per share. Medtronic’s revenue was up 7.7% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. On average, equities analysts predict that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 17th. Investors of record on Friday, September 26th will be given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 3.1%. The ex-dividend date is Friday, September 26th. Medtronic’s payout ratio is 78.24%.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.